Reverse Complement PCR (RC-PCR) technology permits the combined generation and flexible tagging of amplicon constructs from a target sequence or sequences in a single, closed tube amplification and indexing reaction.
NimaGen will utilize the technology to develop and market new kíts and panels for Next Generation Sequencing (NGS), bringing new tools to researchers working in this rapidly developing field.
These kits will augment NimaGen's existing strong portfolio in the capillary sequencing and Next Generation Sequencing market.
Under the terms of the agreement, NimaGen is granted a worldwide license for research applications including the development and sale of products for sample tracking & authentication within laboratories, high throughput screening and diagnostic research. NimaGen B.V. expect the first products to be available to customers in early 2019.